Document:

<PAGE>

                                              *TEXT OMITTED AND FILED SEPARATELY
                                               CONFIDENTIAL TREATMENT REQUESTED
                                           UNDER 17 C.F.R. SECTIONS 200.80(b)(4)
                                                              200.83 an 230.406

                          TECHNOLOGY LICENSE AGREEMENT

                                     BETWEEN

                           ELITRA PHARMACEUTICALS INC.

                                       AND

                              INCYTE GENOMICS, INC.

<PAGE>

                           TECHNOLOGY LICENSE AGREEMENT

         THIS AGREEMENT is entered into as of this 30th day of June, 2000 (the
"EFFECTIVE DATE") by and between ELITRA PHARMACEUTICALS INC. ("ELITRA"), a
Delaware corporation, having its principal place of business at 3510 Dunhill
Street, San Diego, CA 92121, and INCYTE GENOMICS, INC. ("INCYTE"), a Delaware
corporation, having its principal place of business at 3160 Porter Drive, Palo
Alto, CA 94304.

         WHEREAS, Incyte has developed and owns certain computer software
providing analysis and data-management tools for handling complex information
from multiple sources; and

         WHEREAS, ELITRA desires to implement such software at ELITRA; and

         WHEREAS, this Technology License Agreement shall not be considered
valid or binding without execution by both Incyte and ELITRA of the Microbial
Information Agreement of even date herewith; and

         NOW, THEREFORE, Incyte and ELITRA, intending to be legally bound,
hereby agree as follows:

1.       DEFINITIONS.

         When used in this Agreement, the following definitions shall apply:

         "COMMON CODE" shall mean the common source code described in EXHIBIT B
hereto.

         "DOCUMENTATION" shall mean the user's manuals provided to ELITRA along
with the LifeTools-TM- Product.

         "ELITRA AFFILIATE(S)" shall mean any company or entity controlled by,
controlling, or under common control with ELITRA shall include any company one
hundred percent (100%) of whose voting stock or participating profit interest is
owned or controlled, directly or indirectly, by ELITRA, and any company which
owns or controls, directly or indirectly, one hundred percent (100%) of the
voting stock of ELITRA.

         "INCYTE TECHNOLOGY" shall mean Intellectual Property Rights claiming or
covering the use of the LifeTools-TM- Product, the Linux Farm Technology, the
Common Code and the Patent Search Module to the extent owned or controlled by
Incyte and which Incyte has an unrestricted right to license without obligation
of payment to a third party.

         "INSTALLATION SITE(S)" shall mean the research facilities of ELITRA
and/or any ELITRA Affiliate which will have access to the LifeTools-TM- Product,
the Linux Farm Technology, the Common Code and the Patent Search Module subject
to this Agreement.

         "INTELLECTUAL PROPERTY RIGHTS" shall mean all copyrights, trademarks,
service marks, trade secrets, patents, patent applications, moral rights,
contract rights and other proprietary rights.

                                       1.
<PAGE>

         "LIFETOOLS-TM- PRODUCT" shall mean version 3.1 of Incyte's set of
proprietary software modules providing analysis and data-management tools for
handling complex information from multiple sources, together with related
software and documentation, as described generally in EXHIBIT A.

         "LIFETOOLS-TM- PRODUCT SOURCE CODE" shall mean the source code written
for the LifeTools-TM- Product.

         "LINUX FARM TECHNOLOGY" shall mean a software system that provides
customized scheduling functions which distribute tasks over a large number of
computer systems based on Intel microprocessors and the Linux operating system.

         "PARTY" shall mean ELITRA or Incyte and, when used in the plural, shall
mean ELITRA and Incyte.

         "PATENT SEARCH MODULE" shall mean [...***...] and (b) any updates or
improvements to, or products substantially constituting replacements of, the
foregoing.

         "RESEARCH FIELD OF USE" shall mean internal use of the LifeTools-TM-
Product, at ELITRA's or an ELITRA Affiliate's facilities (a) by personnel of
ELITRA or an ELITRA Affiliate or (b) by ELITRA or an ELITRA Affiliate on behalf
of strategic or collaborative partners of ELITRA or otherwise in connection with
ELITRA's drug discovery collaborations, in each case, for research and
development applications in compliance with this Agreement. The Research Field
of Use does not include (i) the right to sell the LifeTools-TM- Product, (ii)
the sale or license of data analysis services (except as set forth in clause (b)
above), or (iii) the use of LifeTools-TM- Product to develop commercial database
products or services.

         "SOFTWARE" as generally used herein shall mean software in various
stages of development or any product thereof and includes without limitation the
literal elements of a program (source code, object code, manuals, instructions
or otherwise), its audiovisual components (menus, screens, structure and
organization), any human or machine readable form of the program, and any
writing or medium in which the program or information therein is stored, written
or described, including without limitation, diagrams, flow charts, designs,
drawings, specifications, models, data, development tools and routines, bug
reports and customer information.

2.       LICENSE GRANT; SOFTWARE USE RESTRICTIONS AND SECURITY REQUIREMENTS.

         2.1      LICENSE GRANT.  Incyte hereby grants to ELITRA:

                           (a)      a non-exclusive, fee-bearing (as set forth
in Section 4.3.2 of the Microbial Information Agreement), perpetual and
irrevocable (unless terminated under Section 5.2) license under Incyte
Technology to use the LifeTools-TM- Product, the Linux Farm Technology, the
Common Code and the Patent Search Module in the Research Field of Use in secure
work facilities at the Installation Sites in accordance with the terms and
conditions of this Agreement; and

                                               *Confidential Treatment Requested

                                       2.
<PAGE>

                           (b)      the right to make up to three (3) copies of
the LifeTools-TM- Product, the Common Code and the Patent Search Module solely
for backup or archival purposes.

         Except as specifically contemplated by the definition of "Research
Field of Use," the foregoing licenses shall not include any right of ELITRA to
market, license, sublicense, manufacture, sell or distribute the LifeTools-TM-
Product, the Linux Farm Technology, the Common Code or the Patent Search Module
for the benefit of a third party.

         2.2      OWNERSHIP. ELITRA hereby acknowledges that (a) Incyte has
expended significant resources and efforts to develop the LifeTools-TM- Product,
the Linux Farm Technology, the Common Code and the Patent Search Module; (b) the
LifeTools-TM- Product, the Linux Farm Technology, the Common Code and the Patent
Search Module represent highly valuable and confidential assets of Incyte; (c)
Incyte is willing to grant ELITRA access to the LifeTools-TM- Product, the Linux
Farm Technology, the Common Code and the Patent Search Module in reliance that
ELITRA shall protect such Software from unauthorized disclosure and use; and (d)
the LifeTools-TM- Product, the Linux Farm Technology, the Common Code and the
Patent Search Module at all times during the term of this Agreement shall remain
the sole and exclusive property of Incyte.

         2.3      RESERVATION OF RIGHTS. Subject to the grant of license rights
ELITRA hereunder, the LifeTools-TM- Product, the Linux Farm Technology, the
Common Code, the Patent Search Module and all proprietary rights, title, and
other intellectual property rights, including, without limitation, patent,
copyright, trademark, service mark, trade secret and trade name rights, in and
to such LifeTools-TM- Product, the Linux Farm Technology, the Common Code and
the Patent Search Module are hereby owned by Incyte. Except as expressly
provided herein, Incyte shall have the sole right to use, copy, modify, adapt,
create derivative works from, distribute and have distributed, sell, sublicense,
license or otherwise dispose of such LifeTools-TM- Product, the Linux Farm
Technology, the Common Code and the Patent Search Module and/or any product(s)
incorporating such LifeTools-TM- Product, the Linux Farm Technology, the Common
Code or the Patent Search Module.

         2.4      RESTRICTIONS ON USE AND DISCLOSURE OF SOFTWARE.

                  2.4.1    DESIGNATED CPU'S. The LifeTools-TM- Product, the
Linux Farm Technology, the Common Code and the Patent Search Module shall only
be installed at each Installation Site on a single hard disk(s) or the hard
disk(s) of a designated file server whereby multiple workstation(s) do not
contain copy(s) of the LifeTools-TM- Product, the Linux Farm Technology, the
Common Code and the Patent Search Module installed, other than ephemerally, on
the workstation hard disk. A back-up computer or file server may be designated
such that a copy of the LifeTools-TM- Product, the Linux Farm Technology, the
Common Code and the Patent Search Module may be installed on this computer in
the event that the primary computer fails. Under no circumstances will the
LifeTools-TM- Product, the Linux Farm Technology, the Common Code or the Patent
Search Module be installed on any designated CPU(s) which would allow
unauthorized network access (E.G., third party access via the Internet other
than as specifically contemplated by the definition of Research Field of Use).
Except as specifically contemplated by the definition of Research Field of Use
or otherwise expressly set forth herein, all access to the LifeTools-TM-
Product, the Linux Farm Technology, the Common Code and the Patent Search

                                       3.
<PAGE>

Module, including access by facilities of ELITRA and ELITRA Affiliates other
than those designated as Installation Sites, is prohibited.

                  2.4.2    NON-DISCLOSURE. Except as expressly provided herein,
ELITRA shall not disclose the LifeTools-TM- Product, the LifeTools-TM- Product
Source Code, the Linux Farm Technology, the Patent Search Module or Confidential
Information of Incyte or transfer the LifeTools-TM- Product, or any portion
thereof, or any modifications thereto, to any third party.

                  2.4.3    NO TRANSFER OR MODIFICATION. Except as expressly
provided herein, ELITRA shall not sublicense, sell, assign, convey, transfer,
publish, display, copy, duplicate, adapt, merge, embed, disassemble, decompile,
translate, reverse engineer or otherwise modify any portion of the LifeTools-TM-
Product, the Linux Farm Technology, the Common Code or the Patent Search Module
(by any means whatsoever whether now known or hereafter invented).
Notwithstanding the foregoing, ELITRA shall have the right to modify the
LifeTools-TM- Product, the Common Code and the Patent Search Module for its
internal use.

                  2.4.4    LOSS OR THEFT. ELITRA promptly shall notify Incyte of
any loss, theft or unauthorized disclosure or use of LifeTools-TM- Product, the
Linux Farm Technology, or the Patent Search Module which comes to ELITRA's
attention.

3.       INTELLECTUAL PROPERTY.

         3.1      THIRD PARTY INTELLECTUAL PROPERTY. Subject to the
warranties made hereunder as to each Party's knowledge of any third party
rights that may be infringed by the uses of the LifeTools-TM- Product, the
Linux Farm Technology, the Common Code and the Patent Search Module as
contemplated herein, ELITRA acknowledges that, [...***...], ELITRA [...***...]
, and it is hereby agreed that it shall be [...***...], if necessary,
[...***...]. SCHEDULE 3.1 attached hereto is a true and complete list of
third party software programs which are required for ELITRA to access and
utilize the LifeTools-TM- Product and the Patent Search Module.

         3.2      DELIVERY. Incyte shall deliver the LifeTools-TM- Product, the
Documentation, the Linux Farm Technology, the Patent Search Module (including
the source code thereof) and the Common Code to ELITRA upon execution of this
Agreement. The LifeTools-TM- Product, the Linux Farm Technology, the Common Code
and the Patent Search Module shall be delivered on a CD-ROM and/or on such other
media as the Parties shall have mutually agreed depending upon the nature and
format of the information being transferred.

4.       PAYMENTS.

         4.1      FEES; PAYMENT TERMS. Payments for access and perpetual license
to the LifeTools-TM- Product, the Linux Farm Technology, the Common Code and the
Patent Search Module and other related payment are included under Article 4 of
the Microbial Information Agreement.

                                               *Confidential Treatment Requested
                                       4.
<PAGE>

5.       TERM; TERMINATION.

         5.1      TERM. This Agreement shall commence as of the Effective Date
and shall continue in full force and effect unless terminated as provided
herein.

         5.2      TERMINATION FOR BREACH. Material failure by either Party to
comply with any of its obligations under this Agreement shall entitle the other
Party to give to the Party in default written notice specifying the nature of
the default and requiring it to cure such default. If such default is not cured
within sixty (60) days after the receipt of such notice, the notifying Party
shall be entitled, without prejudice to any of its other rights conferred on it
by this Agreement, in addition to any other remedies available to it by law or
in equity, immediately to terminate this Agreement by giving notice to the other
Party. The right of a Party to terminate this Agreement, as hereinafter
provided, shall not be affected in any way by its waiver or failure to take
action with respect to any previous default.

         5.3      EFFECT OF TERMINATION. In the event of termination of the
Agreement by Incyte for breach by ELITRA, then it shall be ELITRA's obligation,
at its expense, to discontinue use of the LifeTools-TM- Product, the Linux Farm
Technology, the Common Code and the Patent Search Module, and remove the
LifeTools-TM- Product, the Linux Farm Technology, the Common Code and the Patent
Search Module from each designated CPU, and promptly return any copies thereof
to Incyte, or upon Incyte's written instruction, destroy all portions and copies
of the LifeTools-TM- Product, the Linux Farm Technology, the Common Code and the
Patent Search Module, and thereafter relinquish its rights to the LifeTools-TM-
Product, the Linux Farm Technology, the Common Code and the Patent Search
Module, including any rights to use, copy, modify, adapt, create derivative
works with respect to same.

         5.4      DISPUTE RESOLUTION PROCEDURES. If the Parties cannot resolve a
dispute arising out of or in connection with this Agreement, then any Party may,
by written notice to the other, have such dispute referred to their respective
officers designated below or their respective successors, for attempted
resolution by good faith negotiations within 30 days after such notice is
received:

                      For Incyte:               President

                      For ELITRA:               President

         Any such dispute which is not so resolved between the Parties or the
designated officers of the Parties within such 30 day period shall, upon written
notice from a Party to the other, be resolved by final and binding arbitration
under then current Licensing Agreement Arbitration Rules of the American
Arbitration Association ("AAA"). If the claim is filed by a Party, the venue for
arbitration shall be proximate to that of the other Party. The arbitration shall
be conducted by a panel of three arbitrators who are knowledgeable in the
subject matter which is at issue in the dispute (the "PANEL"). Each Party shall
have the right to appoint one member of the Panel, with the third member to be
mutually agreed by the two Panel members appointed by the Parties, or, failing
such agreement, shall be selected according to the AAA rules. In conducting the
arbitration, the Panel shall determine what discovery will be permitted,
consistent with the goal of limiting the cost and time which the Parties must
expend for discovery (and provided that

                                       5.
<PAGE>

the Panel shall permit such discovery deemed necessary to permit an equitable
resolution of the dispute). The decision of the Panel shall be in writing and
shall set forth the basis therefor. The Parties shall abide by all awards
rendered in arbitration proceedings, and such awards may be enforced and
executed upon in any court having jurisdiction over the Party against whom
enforcement of such award is sought. The Panel shall also determine the
steps, if any, that a Party should take to correct any failure or breach by
such Party pertaining to any such dispute. The Parties shall share equally
the Panel's fees and expenses. The decision of the Panel shall be final and
may be enforced by the Party in whose favor it runs in any court of competent
jurisdiction at the option of such Party. Nothing in this Agreement shall be
deemed to prevent either Party from seeking injunctive relief (or any other
provisional remedy) from any court having jurisdiction over the Parties and
the subject matter of the dispute as necessary to protect either Party's
intellectual property rights.

         5.5      ACCRUED RIGHTS; SURVIVING OBLIGATIONS. Termination of this
Agreement for any reason shall be without prejudice to any rights which shall
have accrued to the benefit of either Party prior to such termination. Upon any
termination of this Agreement, the following provisions will not terminate, but
will continue in full force and effect: Article 2 (License Grant; Software Use
Restrictions and Security Requirements), except that Section 2.1 shall not
survive if Incyte has terminated this Agreement for breach by ELITRA; Section
3.1 (Third Party Intellectual Property); Article 5 (Term; Termination); Section
6.4 (Disclaimers); Article 7 (Indemnity); Article 8 (Miscellaneous Provisions);
and any payment obligations pursuant to ELITRA's rights which have become due
and payable under the appropriate sections of this Agreement prior to the
termination or expiration of this Agreement.

6.       REPRESENTATIONS AND WARRANTIES; COVENANTS.

         6.1      REPRESENTATIONS AND WARRANTIES OF INCYTE. Incyte represents
and warrants to ELITRA as follows:

                           (a)      Incyte has full corporate power and
authority to enter into this Agreement and to perform its obligations hereunder.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of Incyte. This Agreement has been duly executed
and delivered by Incyte and constitutes a valid and binding obligation of
Incyte, enforceable against it in accordance with its terms.

                           (b)      Neither the execution, delivery nor
performance of this Agreement by Incyte will conflict with or result in the
breach of any agreement to which Incyte is a party or any instrument, document,
law, regulation, judgment, order or decree by which it or its assets are bound.

                           (c)      There are no material adverse proceedings,
claims or actions pending, or to the best of Incyte's knowledge, threatened,
relating to the Incyte Technology as of the Effective Date of this Agreement
which would materially interfere with Incyte's performance of its obligations
under this Agreement. Further, Incyte shall disclose to ELITRA any material
adverse proceedings, claims or action that arise and come to the knowledge of
Incyte without

                                       6.
<PAGE>

undertaking a special investigation, relating to Incyte Technology, which
would materially interfere with Incyte's performance of its obligations under
this Agreement.

                           (d)      Incyte is the [...***...], and [...***...].
Incyte is [...***...]. Except as set forth on Schedule 3.1, Incyte is
[...***...].

                           (e)      Incyte requires [...***...], and
requiring [...***...] made within the [...***...], and only [...***...]
pursuant to [...***...].

                           (f)      For a period of [...***...] after
[...***...] is provided to [...***...]. This warranty does not apply to
[...***...].

                           (g)      For a period of [...***...], when
[...***...]. Incyte does not warrant that [...***...]. Incyte will,
[...***...]. Any such [...***...] provided to [...***...].

                           (h)      The term [...***...] means any [...***...]
 to (a) [...***...] or (b) [...***...]. Incyte represents and warrants that
the [...***...]

                                               *Confidential Treatment Requested
                                       7.
<PAGE>

[...***...]. Without limiting this warranty, [...***...] will use a
[...***...]. ELITRA acknowledges that [...***...]. Incyte's sole obligation
if [...***...], will be to [...***...], as applicable, on [...***...].

         6.2      REPRESENTATIONS AND WARRANTIES OF ELITRA. ELITRA represents
and warrants to Incyte as follows:

                           (a)      ELITRA has full corporate power and
authority to enter into this Agreement and to perform its obligations hereunder.
The execution and delivery of this Agreement and the consummation of the
transactions contemplated hereby have been duly authorized by all necessary
corporate action on the part of ELITRA. This Agreement has been duly executed
and delivered by ELITRA and constitutes a valid and binding obligation of
ELITRA, enforceable against it in accordance with its terms.

                           (b)      Neither the execution, delivery nor
performance of this Agreement by ELITRA will conflict with or result in the
breach of any agreement to which ELITRA is a party or any instrument, document,
law, regulation, judgment, order or decree by which it or its assets are bound.

         6.3      COMPLIANCE WITH LAW. Each Party shall be responsible for
compliance with all applicable product safety, product testing, product
labeling, package marking, and product advertising laws and regulations with
respect to its own activities and commercial products. Further, ELITRA and
Incyte shall each comply with the regulations of the United States and any other
relevant jurisdiction concerning any export or other transfer of technology,
services, or products.

         6.4      DISCLAIMERS.

                           (a)      EXCEPT AS OTHERWISE PROVIDED IN THIS
AGREEMENT, INCYTE DOES NOT MAKE ANY AND EXPRESSLY DISCLAIMS ALL WARRANTIES WITH
RESPECT TO THE LIFETOOLS-TM- PRODUCT, THE LINUX FARM TechnTECHNOLOGY, THE COMMON
CODE OR THE PATENT SEARCH MODULE, WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED,
OR ARISING BY USAGE OF TRADE OR COURSE OF DEALING INCLUDING, WITHOUT LIMITATION,
THE WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.

                                               *Confidential Treatment Requested
                                       8.
<PAGE>

                           (b)      EXCEPT AS EXPLICITLY STATED HEREIN, NEITHER
PARTY WILL BE LIABLE FOR ECONOMIC, INCIDENTAL, CONSEQUENTIAL, INDIRECT, SPECIAL
OR EXEMPLARY DAMAGES, WHETHER CLAIMED UNDER CONTRACT, TORT OR ANY OTHER LEGAL
THEORY ARISING FROM SUCH PARTY'S ACTIVITIES UNDER THIS AGREEMENT.

7.       INDEMNITY.

         7.1      INDEMNIFICATION BY INCYTE. Incyte shall indemnify and hold
ELITRA and its directors, officers, employees, agents, representatives and
affiliates harmless from and against any loss, liability, cost or expense
(including, but not limited to, reasonable attorneys' fees and costs) arising
from (i) [...***...], or (ii) [...***...]; except to the extent such loss,
liability, cost or expense (including attorney's fees and costs) is
attributable to: (a) a violation of law, regulation or court order by ELITRA,
(b) a violation of any contractual or fiduciary duty (including
misappropriation of trade secrets) owed by ELITRA to a third party, (c)
recklessness or intentional misconduct of ELITRA, (d) any breach of this
Agreement or misrepresentation contained herein by ELITRA, or (e)
infringement by ELITRA (other than by use of the LifeTools-TM-Product, the
Linux Farm Technology, or the Patent Search Module or any portion thereof) of
any third party's patent rights, copyrights or other intellectual property
rights.

         7.2      INDEMNIFICATION BY ELITRA. ELITRA shall indemnify and hold
Incyte and its directors, officers, employees, agents, representatives and
affiliates harmless from and against any loss, liability, cost or expense
(including, but not limited to, reasonable attorneys' fees and costs) arising
from [...***...]; except to the extent such loss liability, cost or expense
(including attorney's fees and costs) is attributable to: (i) a violation of
law, regulation or court order by Incyte, (ii) a violation of any contractual
or fiduciary duty (including misappropriation of trade secrets) owed by
Incyte to a third party, (iii) recklessness or intentional misconduct of
Incyte, (iv) any breach of this Agreement or misrepresentation contained
herein by Incyte, or (v) infringement by Incyte of any third party's patent
rights, copyrights or other intellectual property rights.

         7.3      INDEMNIFICATION PROCEDURES. If any claim is made against
either Party under Sections 7.1 or 7.2 above for which indemnification is
available hereunder, the indemnifying Party, at its option, shall:

                           (a)      defend the other Party against such claim;

                           (b)      acquire for the other Party the right to
continue using any Software or product licensed hereunder that is the subject of
such claim;

                                               *Confidential Treatment Requested
                                       9.
<PAGE>

                           (c)      replace any Software or product licensed
hereunder with other Software or product for which there exists no infringement
claim, which serves materially the same purpose and function as the claimed
infringing Software or product; or

                           (d)      modify the Software or product to make it
non-infringing;

PROVIDED, HOWEVER, that no Party shall have any liability or obligation to the
other under this Section 7.3 if any such infringement claim is based upon or
arises out of:

                           (a)      any modification by the indemnified Party of
any portion of any Software or data not authorized by the indemnifying Party in
writing unless without such modifications the Software would be infringing;

                           (b)      the use of the any Software or product in
violation of the license granted in this Agreement; or

                           (c)      a patent, copyright or other intellectual
property right claim in which the indemnified Party or any affiliate thereof has
any direct or indirect interest by license or otherwise; or

                           (d)      use of old Software after receipt or
replacement of modified Software under (iii) or (iv) above.

If the indemnifying Party elects (i) above, the indemnifying Party, at its
expense, shall have the right to control the defense and settlement of any such
claim and the indemnified Party shall reasonably cooperate with the indemnifying
Party, at the indemnifying Party's expense, in such defense and settlement. If
the indemnifying Party elects (iii) above, the indemnified Party shall return to
the indemnifying Party the claimed infringing Software or product, along with
any copies, duplicates and other manifestations thereof in whatever form.

This Section 7.3 states a Party's entire liability and obligation, and the other
Party's exclusive remedy, for infringement with respect to the first Party's
software.

8.       MISCELLANEOUS PROVISIONS.

         8.1      NO PARTNERSHIP. Nothing in this Agreement is intended or shall
be deemed to constitute a partnership, agency, distributorship,
employer-employee or joint venture relationship between the Parties. No Party
shall incur any debts or make any commitments for the other, except to the
extent, if at all, specifically provided herein.

         8.2      ASSIGNMENTS. Neither Party shall assign any of its rights
or obligations hereunder except: (i) [...***...]; (ii) in the case of
[...***...], to any of [...***...], and in either case, provided that the
[...***...], as applicable; (iii) with respect to either Party [...***...]

                                               *Confidential Treatment Requested
                                     10.
<PAGE>

[...***...], provided that the [...***...]; (iv) [...***...]. This Agreement
shall be binding, upon the successors and permitted assigns of the Parties.
Any assignment not in accordance with the above shall be void. To the extent
that any assignment by ELITRA hereunder would directly result in an increase
in any withholding taxes for which Incyte is responsible under this
Agreement, ELITRA shall be responsible for such additional taxes.

         8.3      NO TRADEMARK RIGHTS. Except as otherwise provided herein, no
right, express or implied, is granted by this Agreement to use in any manner the
names "Incyte" or "ELITRA", or any other trade name or trademark of Incyte or
ELITRA or their affiliates in connection with the performance of this Agreement.

         8.4      PUBLIC ANNOUNCEMENTS. Any and all public announcements
concerning this Agreement or the subject matter hereof shall be governed by the
provisions of Section 8.4 of the Microbial Information Agreement.

         8.5      ENTIRE AGREEMENT OF THE PARTIES; AMENDMENTS. This Agreement
and the other agreements between the Parties of even date herewith constitute
and contain the entire understanding and agreement of the Parties and cancel and
supersede any and all prior negotiations, correspondence, representations,
understandings and agreements, whether verbal or written, between the Parties
respecting the subject matter hereof, including, without limitation, the Prior
Agreement and all financial obligations of ELITRA to Incyte thereunder (whether
or not accrued as of the Effective Date hereof); PROVIDED, HOWEVER, that the
Confidential Disclosure Agreement between the Parties dated March 31, 2000 shall
remain in full force and effect in accordance with its terms. No waiver,
modification or amendment of any provision of this Agreement shall be valid or
effective unless made in writing and signed by a duly authorized officer of each
of the Parties.

         8.6      APPLICABLE LAW. This Agreement shall be governed by and
interpreted in accordance with the laws of the State of California, without
reference to the conflicts of law principles thereof. The parties expressly
exclude application of the United Nations Convention for the International Sale
of Goods.

         8.7      NOTICES AND DELIVERIES. Any notice, requests, delivery,
approval or consent required or permitted to be given under this Agreement shall
be in writing and shall be deemed to have been sufficiently given if delivered
in person, transmitted by commercial overnight courier, or transmitted by telex
telegram or telecopy (facsimile, with confirmed receipt) to the Party to whom it
is directed at its address shown below or such other address as such Party shall
have last given by notice to the other Party (referred to herein as "notice").
All notices shall be effective upon receipt.

                                               *Confidential Treatment Requested
                                     11.

<PAGE>

         If to Incyte, addressed to:

                  Incyte Genomics, Inc.
                  3160 Porter Drive
                  Palo Alto, CA  94304
                  Fax: (650) 845-4574
                  Attn:  Roy Whitfield, Chief Executive Officer

         If to ELITRA, addressed to:

                  ELITRA Pharmaceuticals Inc.
                  3510 Dunhill Street
                  San Diego, CA  92121
                  Fax: (858) 410-3810
                  Attn:  Harry Hixson, Ph.D., Chief Executive Officer and
                         Chairman

         8.8      AFFILIATE PERFORMANCE. To the extent that any ELITRA Affiliate
has access to the LifeTools-TM- Product or the Patent Search Module, has the
right to receive any other rights or benefits under this Agreement or otherwise
is obligated to perform any obligations under this Agreement, ELITRA shall cause
such ELITRA Affiliate to perform in full, when due, all applicable obligations
under this Agreement to the same extent as if such ELITRA Affiliate were a party
to this Agreement; provided, however, that nothing in this Section 8.8 shall
expand the rights or benefits of ELITRA or ELITRA Affiliates, or the obligations
of Incyte, beyond those otherwise expressly set forth in this Agreement. ELITRA
shall guaranty timely performance in full by such ELITRA Affiliate of all such
obligations. A breach by such ELITRA Affiliate of any such obligation shall
constitute a breach by ELITRA of this Agreement.

         8.9      COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original and all of which
together shall constitute one and the same instrument.

                                     12.

<PAGE>

         IN WITNESS WHEREOF, the Parties have caused this Agreement to be
executed by their respective duly authorized officers as of the Effective Date.

                                      INCYTE GENOMICS, INC.

                                      By:  /s/ Randy Scott
                                         -------------------------------------

                                      Name:  Randy Scott
                                           -----------------------------------

                                      Title:  President
                                            ----------------------------------

                                      Date:  6/30/00
                                           -----------------------------------

                                      ELITRA PHARMACEUTICALS INC.

                                      By:  /s/ Harry F. Hixson, Jr.
                                         -------------------------------------

                                      Name:  Harry F. Hixson, Jr.
                                           -----------------------------------

                                      Title:  Chief Executive Officer
                                            ----------------------------------

                                      Date:  6/30/00
                                           -----------------------------------

                 SIGNATURE PAGE TO TECHNOLOGY LICENSE AGREEMENT
                                     13.

<PAGE>

                                    EXHIBIT A

                         LIFETOOLS-TM- PRODUCT OVERVIEW

LIFETOOLS DESCRIPTION

[...***...]

                                               *Confidential Treatment Requested
                                     A-1.

<PAGE>

[...***...]

                                               *Confidential Treatment Requested
                                     A-2.

<PAGE>

[...***...]

                                               *Confidential Treatment Requested
                                     A-3.
<PAGE>

                                    EXHIBIT B

                                   COMMON CODE

[... *** ...]

                                     B-1       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

[... *** ...]

                                     B-2       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

[... *** ...]

                                     B-3       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

[... *** ...]

                                     B-4       *CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

[... *** ...]

                                     B-5       *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-6    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-7    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-8    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-9    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-10    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-11    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-12    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-13    *CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

[... *** ...]

                                       B-14    *CONFIDENTIAL TREATMENT REQUESTED<PAGE>

THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED, OR ANY STATE SECURITIES LAWS. THEY MAY NOT BE SOLD OR OFFERED FOR SALE
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT AS TO THE SECURITIES UNDER
SAID ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR THE AVAILABILITY OF AN
EXEMPTION FROM REGISTRATION UNDER SAID ACT AND ANY APPLICABLE STATE SECURITIES
LAWS.

                                       NO.
                           STOCK SUBSCRIPTION WARRANT

                           TO PURCHASE COMMON STOCK OF

                     ELITRA PHARMACEUTICALS (THE "COMPANY")

                    DATE OF INITIAL ISSUANCE: JULY 27, 2000

         THIS CERTIFIES THAT for value received, TBCC FUNDING TRUST II or its
registered assigns (hereinafter called the "Holder") is entitled to purchase
from the Company, at any time during the Term of this Warrant, Twenty-Six
Thousand Fifty (26,050) shares of common stock, $0.01 par value, of the Company
(the "Common Stock"), at the Warrant Price, payable as provided herein. The
exercise of this Warrant shall be subject to the provisions, limitations and
restrictions herein contained, and may be exercised in whole or in part.

SECTION 1.  DEFINITIONS.

         For all purposes of this Warrant, the following terms shall have the
meanings indicated:

         COMMON STOCK - shall mean and include the Company's authorized Common
Stock, $0.01 par value, as constituted at the date hereof.

         EXCHANGE ACT - shall mean the Securities Exchange Act of 1934, as
amended from time to time.

         SECURITIES ACT - the Securities Act of 1933, as amended.

         TERM OF THIS WARRANT - shall mean the period beginning on the date of
initial issuance hereof and ending on July 27, 2007.

         WARRANT PRICE - per share shall be equal to the lower of: a) $4.80 per
share; or b) the price per share of the next "non-partner" round of venture
capital financing if such financing occurs within 90 days of June 13, 2000. In
the event that the next "non-partner" round of venture capital financing does
not occur for any reason by September 13, 2000, the price per share shall be
$4.80.

         WARRANTS - this Warrant and any other Warrant or Warrants issued in
connection with a Commitment Letter dated June 13, 2000 executed by the Company
and Transamerica Business Credit

<PAGE>

Corporation (the "Commitment Letter") to the original holder of this Warrant, or
any transferees from such original holder or this Holder.

         WARRANT SHARES - shares of Common Stock purchased or purchasable by the
Holder of this Warrant upon the exercise hereof.

SECTION 2.  EXERCISE OF WARRANT.

         2.1. PROCEDURE FOR EXERCISE OF WARRANT. To exercise this Warrant in
whole or in part (but not as to any fractional share of Common Stock), the
Holder shall deliver to the Company at its office referred to in Section 13
hereof at any time and from time to time during the Term of this Warrant: (i)
the Notice of Exercise in the form attached hereto, (ii) cash, certified or
official bank check payable to the order of the Company, wire transfer of funds
to the Company's account, or evidence of any indebtedness of the Company to the
Holder (or any combination of any of the foregoing) in the amount of the Warrant
Price for each share being purchased, and (iii) this Warrant. Notwithstanding
any provisions herein to the contrary, if the Current Market Price (as defined
in Section 5) is greater than the Warrant Price (at the date of calculation, as
set forth below), in lieu of exercising this Warrant as hereinabove permitted,
the Holder may elect to receive shares of Common Stock equal to the value (as
determined below) of this Warrant (or the portion thereof being canceled) by
surrender of this Warrant at the office of the Company referred to in Section 13
hereof, together with the Notice of Exercise, in which event the Company shall
issue to the Holder that number of shares of Common Stock computed using the
following formula:

                               CS = WCS x (CMP-WP)
                                    --------------
                                       CMP

Where

            CS          equals the number of shares of Common Stock to be issued
                        to the Holder

            WCS         equals the number of shares of Common Stock purchasable
                        under the Warrant or, if only a portion of the Warrant
                        is being exercised, the portion of the Warrant being
                        exercised (at the date of such calculation)

            CMP         equals the Current Market Price (at the date of such
                        calculation)

            WP          equals the Warrant Price (as adjusted to the date of
                        such calculation)

In the event of any exercise of the rights represented by this Warrant, a
certificate or certificates for the shares of Common Stock so purchased,
registered in the name of the Holder or such other name or names as may be
designated by the Holder, shall be delivered to the Holder hereof within a
reasonable time, not exceeding fifteen (15) days, after the rights represented
by this Warrant shall have been so exercised; and, unless this Warrant has
expired, a new Warrant representing the number of shares (except a remaining
fractional share), if any, with respect to which this Warrant shall not then
have been exercised shall also be issued to the Holder hereof within such time.
The person in whose name any certificate for shares of Common Stock is issued
upon exercise of this Warrant shall for all purposes be deemed to have become
the holder of record of such shares on the date on which the Warrant was
surrendered and payment of the Warrant Price and any applicable taxes was made,
irrespective of the date of delivery of such certificate, except that, if the
date of such surrender and payment is a date when the stock transfer

                                      -2-
<PAGE>

books of the Company are closed, such person shall be deemed to have become the
holder of such shares at the close of business on the next succeeding date on
which the stock transfer books are open.

         2.2. TRANSFER RESTRICTION LEGEND. Each certificate for Warrant Shares
shall bear the following legend (and any additional legend required by (i) any
applicable state securities laws and (ii) any securities exchange upon which
such Warrant Shares may, at the time of such exercise, be listed) on the face
thereof unless at the time of exercise such Warrant Shares shall be registered
under the Securities Act:

         "The shares represented by this certificate have not been registered
         under the Securities Act of 1933, as amended, and may not be sold or
         transferred in the absence of such registration or an exemption
         therefrom under said Act."

Any certificate issued at any time in exchange or substitution for any
certificate bearing such legend (except a new certificate issued upon completion
of a public distribution under a registration statement of the securities
represented thereby) shall also bear such legend unless, in the opinion of
counsel for the holder thereof (which counsel shall be reasonably satisfactory
to counsel for the Company) the securities represented thereby are not, at such
time, required by law to bear such legend.

SECTION 3. COVENANTS AS TO COMMON STOCK. The Company covenants and agrees that
all shares of Common Stock that may be issued upon the exercise of the rights
represented by this Warrant will, upon issuance, be validly issued, fully paid
and nonassessable, and free from all taxes, liens and charges with respect to
the issue thereof. The Company further covenants and agrees that it will pay
when due and payable any and all federal and state taxes which may be payable in
respect of the issue of this Warrant or any Common Stock or certificates
therefor issuable upon the exercise of this Warrant. The Company further
covenants and agrees that the Company will at all times have authorized and
reserved, free from preemptive rights, a sufficient number of shares of Common
Stock to provide for the exercise of the rights represented by this Warrant. The
Company further covenants and agrees that if any shares of capital stock to be
reserved for the purpose of the issuance of shares upon the exercise of this
Warrant require registration with or approval of any governmental authority
under any federal or state law before such shares may be validly issued or
delivered upon exercise, then the Company will in good faith and as
expeditiously as possible endeavor to secure such registration or approval, as
the case may be. If and so long as the Common Stock issuable upon the exercise
of this Warrant is listed on any national securities exchange, the Company will,
if permitted by the rules of such exchange, list and keep listed on such
exchange, upon official notice of issuance, all shares of such Common Stock
issuable upon exercise of this Warrant.

SECTION 4. ADJUSTMENT OF NUMBER OF SHARES. Upon each adjustment of the Warrant
Price as provided in Section 5, the Holder shall thereafter be entitled to
purchase, at the Warrant Price resulting from such adjustment, the number of
shares (calculated to the nearest tenth of a share) obtained by multiplying the
Warrant Price in effect immediately prior to such adjustment by the number of
shares purchasable pursuant hereto immediately prior to such adjustment and
dividing the product thereof by the Warrant Price resulting from such
adjustment.

SECTION 5. ADJUSTMENT OF WARRANT PRICE. The Warrant Price shall be subject to
adjustment from time to time as follows:

                                      -3-
<PAGE>

         (i) If, at any time during the Term of this Warrant, the number of
shares of Common Stock outstanding is increased by a stock dividend payable in
shares of Common Stock or by a subdivision or split-up of shares of Common
Stock, then, following the record date fixed for the determination of holders of
Common Stock entitled to receive such stock dividend, subdivision or split-up,
the Warrant Price shall be appropriately decreased so that the number of shares
of Common Stock issuable upon the exercise hereof shall be increased in
proportion to such increase in outstanding shares.

         (ii) If, at any time during the Term of this Warrant, the number of
shares of Common Stock outstanding is decreased by a combination of the
outstanding shares of Common Stock, then, following the record date for such
combination, the Warrant Price shall appropriately increase so that the number
of shares of Common Stock issuable upon the exercise hereof shall be decreased
in proportion to such decrease in outstanding shares.

         (iii) In case, at any time during the Term of this Warrant, the Company
shall declare a cash dividend upon its Common Stock payable otherwise than out
of earnings or earned surplus or shall distribute to holders of its Common Stock
shares of its capital stock (other than Common Stock), stock or other securities
of other persons, evidences of indebtedness issued by the Company or other
persons, assets (excluding cash dividends and distributions) or options or
rights (excluding options to purchase and rights to subscribe for Common Stock
or other securities of the Company convertible into or exchangeable for Common
Stock), then, in each such case, immediately following the record date fixed for
the determination of the holders of Common Stock entitled to receive such
dividend or distribution, the Warrant Price in effect thereafter shall be
determined by multiplying the Warrant Price in effect immediately prior to such
record date by a fraction of which the numerator shall be an amount equal to the
difference of (x) the Current Market Price of one share of Common Stock minus
(y) the fair market value (as determined by the Board of Directors of the
Company, whose determination shall be conclusive) of the stock, securities,
evidences of indebtedness, assets, options or rights so distributed in respect
of one share of Common Stock, and of which the denominator shall be such Current
Market Price.

         (iv) All calculations under this Section 5 shall be made to the nearest
cent or to the nearest one-tenth (1/10) of a share, as the case may be.

         (v) For the purpose of any computation pursuant to this Section 5, the
Current Market Price at any date of one share of Common Stock shall be deemed to
be the average of the daily closing prices for the 15 consecutive business days
ending on the last business day before the day in question (as adjusted for any
stock dividend, split, combination or reclassification that took effect during
such 15 business day period). The closing price for each day shall be the last
reported sales price regular way or, in case no such reported sales took place
on such day, the average of the last reported bid and asked prices regular way,
in either case on the principal national securities exchange on which the Common
Stock is listed or admitted to trading or as reported by Nasdaq (or if the
Common Stock is not at the time listed or admitted for trading on any such
exchange or if prices of the Common Stock are not reported by Nasdaq then such
price shall be equal to the average of the last reported bid and asked prices on
such day as reported by The National Quotation Bureau Incorporated or any
similar reputable quotation and reporting service, if such quotation is not
reported by The National Quotation Bureau Incorporated); provided, however, that
if the Common Stock is not traded in such manner that the quotations referred to
in this clause (v) are available for the period required hereunder, the Current
Market Price shall be determined in good faith by the Board of Directors of the
Company or, if such determination cannot be made, by a nationally

                                      -4-
<PAGE>

recognized independent investment banking firm selected by the Board of
Directors of the Company (or if such selection cannot be made, by a nationally
recognized independent investment banking firm selected by the American
Arbitration Association in accordance with its rules).

         (vi) Whenever the Warrant Price shall be adjusted as provided in
Section 5, the Company shall prepare a statement showing the facts requiring
such adjustment and the Warrant Price that shall be in effect after such
adjustment. The Company shall cause a copy of such statement to be sent by mail,
first class postage prepaid, to each Holder of this Warrant at its, his or her
address appearing on the Company's records. Where appropriate, such copy may be
given in advance and may be included as part of the notice required to be mailed
under the provisions of subsection (x) of this Section 5.

         (vii) Adjustments made pursuant to clauses (i), (ii) and (iii) above
shall be made on the date such dividend, subdivision, split-up, combination or
distribution, as the case may be, is made, and shall become effective at the
opening of business on the business day next following the record date for the
determination of stockholders entitled to such dividend, subdivision, split-up,
combination or distribution.

         (viii) In the event the Company shall propose to take any action of the
types described in clauses (i), (ii), or (iii) of this Section 5, the Company
shall forward, at the same time and in the same manner, to the Holder of this
Warrant such notice, if any, which the Company shall give to the holders of
capital stock of the Company.

         (ix) In any case in which the provisions of this Section 5 shall
require that an adjustment shall become effective immediately after a record
date for an event, the Company may defer until the occurrence of such event
issuing to the Holder of all or any part of this Warrant which is exercised
after such record date and before the occurrence of such event the additional
shares of capital stock issuable upon such exercise by reason of the adjustment
required by such event over and above the shares of capital stock issuable upon
such exercise before giving effect to such adjustment exercise; provided,
however, that the Company shall deliver to such Holder a due bill or other
appropriate instrument evidencing such Holder's right to receive such additional
shares upon the occurrence of the event requiring such adjustment.

SECTION 6.  OWNERSHIP.

         6.1. OWNERSHIP OF THIS WARRANT. The Company may deem and treat the
person in whose name this Warrant is registered as the holder and owner hereof
(notwithstanding any notations of ownership or writing hereon made by anyone
other than the Company) for all purposes and shall not be affected by any notice
to the contrary until presentation of this Warrant for registration of transfer
as provided in this Section 6.

         6.2. TRANSFER AND REPLACEMENT. This Warrant and all rights hereunder
are transferable in whole or in part upon the books of the Company by the Holder
hereof in person or by duly authorized attorney, and a new Warrant or Warrants,
of the same tenor as this Warrant but registered in the name of the transferee
or transferees (and in the name of the Holder, if a partial transfer is
effected) shall be made and delivered by the Company upon surrender of this
Warrant duly endorsed, at the office of the Company referred to in Section 13
hereof. Upon receipt by the Company of evidence reasonably satisfactory to it of
the loss, theft or destruction, and, in such case, of indemnity or security
reasonably satisfactory to it, and upon surrender of this Warrant if mutilated,
the Company will make and deliver a

                                      -5-
<PAGE>

new Warrant of like tenor, in lieu of this Warrant; provided that if the Holder
hereof is an instrumentality of a state or local government or an institutional
holder or a nominee for such an instrumentality or institutional holder an
irrevocable agreement of indemnity by such Holder shall be sufficient for all
purposes of this Section 6, and no evidence of loss or theft or destruction
shall be necessary. This Warrant shall be promptly cancelled by the Company upon
the surrender hereof in connection with any transfer or replacement. Except as
otherwise provided above, in the case of the loss, theft or destruction of a
Warrant, the Company shall pay all expenses, taxes and other charges payable in
connection with any transfer or replacement of this Warrant, other than stock
transfer taxes (if any) payable in connection with a transfer of this Warrant,
which shall be payable by the Holder. Holder will not transfer this Warrant and
the rights hereunder except in compliance with federal and state securities
laws.

SECTION 7. MERGERS, CONSOLIDATION, SALES. In the case of any proposed
consolidation or merger of the Company with another entity, or the proposed sale
of all or substantially all of its assets to another person or entity, or any
proposed reorganization or reclassification of the capital stock of the Company,
then, as a condition of such consolidation, merger, sale, reorganization or
reclassification, lawful and adequate provision shall be made whereby the Holder
of this Warrant shall thereafter have the right to receive upon the basis and
upon the terms and conditions specified herein, in lieu of the shares of the
Common Stock of the Company immediately theretofore purchasable hereunder, such
shares of stock, securities or assets as may (by virtue of such consolidation,
merger, sale, reorganization or reclassification) be issued or payable with
respect to or in exchange for the number of shares of such Common Stock
purchasable hereunder immediately before such consolidation, merger, sale,
reorganization or reclassification. In any such case appropriate provision shall
be made with respect to the rights and interests of the Holder of this Warrant
to the end that the provisions hereof shall thereafter be applicable as nearly
as may be, in relation to any shares of stock, securities or assets thereafter
deliverable upon the exercise of this Warrant.

SECTION 8. NOTICE OF DISSOLUTION OR LIQUIDATION. In case of any distribution of
the assets of the Company in dissolution or liquidation (except under
circumstances when the foregoing Section 7 shall be applicable), the Company
shall give notice thereof to the Holder hereof and shall make no distribution to
shareholders until the expiration of thirty (30) days from the date of mailing
of the aforesaid notice and, in any case, the Holder hereof may exercise this
Warrant within thirty (30) days from the date of the giving of such notice, and
all rights herein granted not so exercised within such thirty-day period shall
thereafter become null and void.

SECTION 9. NOTICE OF EXTRAORDINARY DIVIDENDS. If the Board of Directors of the
Company shall declare any dividend or other distribution on its Common Stock
except out of earned surplus or by way of a stock dividend payable in shares of
its Common Stock, the Company shall mail notice thereof to the Holder hereof not
less than thirty (30) days prior to the record date fixed for determining
shareholders entitled to participate in such dividend or other distribution, and
the Holder hereof shall not participate in such dividend or other distribution
unless this Warrant is exercised prior to such record date. The provisions of
this Section 9 shall not apply to distributions made in connection with
transactions covered by Section 7.

SECTION 10. FRACTIONAL SHARES. Fractional shares shall not be issued upon the
exercise of this Warrant but in any case where the Holder would, except for the
provisions of this Section 10, be entitled under the terms hereof to receive a
fractional share upon the complete exercise of this Warrant, the Company shall,
upon the exercise of this Warrant for the largest number of whole shares then
called for, pay a sum in cash equal to the excess of the value of such
fractional share (determined in such reasonable

                                      -6-
<PAGE>

manner as may be prescribed in good faith by the Board of Directors of the
Company) over the Warrant Price for such fractional share.

SECTION 11. SPECIAL ARRANGEMENTS OF THE COMPANY. The Company covenants and
agrees that during the Term of this Warrant, unless otherwise approved by the
Holder of this Warrant:

         11.1. WILL RESERVE SHARES. The Company will reserve and set apart and
have available for issuance at all times, free from preemptive or other
preferential rights, the number of shares of authorized but unissued Common
Stock deliverable upon the exercise of this Warrant.

         11.2. WILL NOT AMEND CERTIFICATE. The Company will not amend its
Certificate of Incorporation to eliminate as an authorized class of capital
stock that class denominated as "Common Stock" on the date hereof.

         11.3. WILL BIND SUCCESSORS. This Warrant shall be binding upon any
corporation or other person or entity succeeding to the Company by merger,
consolidation or acquisition of all or substantially all of the Company's
assets.

SECTION 12.  REGISTRATION RIGHTS; ETC.

         12.1. CERTAIN DEFINITIONS. As used in this Section 12, the following
terms shall have the following respective meanings:

         "Commission" shall mean the Securities and Exchange Commission or any
other federal agency at the time administering the Securities Act.

         "Registrable Securities" shall mean the Warrant Shares less any Warrant
Shares theretofore sold to the public or in a private placement.

         The terms "register," "registered" and "registration" shall refer to a
registration effected by preparing and filing a registration statement in
compliance with the Securities Act and applicable rules and regulations
thereunder, and the effectiveness of such registration statement.

         "Registration Expenses" shall mean all expenses incurred by the Company
in compliance with Section 12.2 hereof, including, without limitation, all
registration and filing fees, printing expenses, fees and disbursements of
counsel for the Company, blue sky fees and expenses, and the expense of any
special audits incident to or required by any such registration (but excluding
the compensation of regular employees of the Company, which shall be paid in any
event by the Company).

         "Selling Expenses" shall mean all underwriting discounts and selling
commissions applicable to the sale of Registrable Securities, all fees and
disbursements of counsel for any Holder and any blue sky fees and expenses
excluded from the definition of "Registration Expenses."

         "Holder" shall mean any holder of outstanding Warrant Shares or
Registrable Securities which (except for purposes of determining "Holders" under
Section 12.5 hereof) have not been sold to the public.

                                      -7-
<PAGE>

         "Other Shareholders" shall mean holders of securities of the Company
who are entitled by contract with the Company or who are permitted by the
Company to have securities included in a registration of the Company's
securities.

         12.2.    COMPANY REGISTRATION.

                  (a) NOTICE OF REGISTRATION. If the Company shall determine to
register any of its securities either for its own account or the account of a
security holder or holders, other than a registration relating solely to
employee benefit plans, or a registration relating solely to a Commission Rule
145 transaction, or a registration on any registration form which does not
permit secondary sales, the Company will:

                           (i) promptly give to each Holder written notice
thereof (which shall include a list of the jurisdictions in which the Company
intends to attempt to qualify such securities under the applicable blue sky or
other state securities laws); and

                           (ii) include in such registration (and any related
qualification under blue sky laws or other compliance), and in any underwriting
involved therein, all the Registrable Securities specified in a written request
or requests, made by any Holder within fifteen (15) days after receipt of the
written notice from the Company described in clause (i) above, subject to any
limitations on the number of shares as set forth in Section 12.2(b) below.

                  (b) UNDERWRITING. If the registration of which the Company
gives notice is for a registered public offering involving an underwriting, the
Company shall so advise the Holders as part of the written notice given pursuant
to Section 12.2(a)(i). In such event, the right of any Holder to registration
pursuant to Section 12.2 shall be conditioned upon such Holder's participation
in such underwriting and the inclusion of such Holder's Registrable Securities
in the underwriting to the extent provided herein. All Holders proposing to
distribute their securities through such underwriting shall (together with the
Company, directors and officers and the Other Shareholders distributing their
securities through such underwriting) enter into an underwriting agreement in
customary form with the underwriter or underwriters selected for underwriting by
the Company.

         Notwithstanding any other provision of this Section 12.2, if the
underwriter determines that marketing factors require a limitation on the number
of shares to be underwritten, the underwriter may (subject to the allocation
priority set forth below) exclude from such registration and underwriting some
or all of the Registrable Securities which would otherwise be underwritten
pursuant hereto. The Company shall so advise all holders of securities
requesting registration, and the number of shares of securities that are
entitled to be included in the registration and underwriting shall be allocated
in the following manner. The number of shares that may be included in the
registration and underwriting on behalf of such Holders, directors and officers
and Other Shareholders shall be allocated among such Holders, directors and
officers and Other Shareholders in proportion, as nearly as practicable, to the
respective amounts of Registrable Securities and other securities which they had
requested to be included in such registration at the time of filing the
registration statement.

         If any Holder of Registrable Securities or any officer, director or
Other Shareholder disapproves of the terms of any such underwriting, it, he or
she may elect to withdraw therefrom by written notice to the Company and the
underwriter. Any Registrable Securities or other securities excluded or
withdrawn from such underwriting shall be withdrawn from such registration.

                                      -8-
<PAGE>

         12.3. REGISTRATION RIGHTS. In the event that the Company grants
registration rights, including demand registration rights, to any other holder
of securities of the Company, the Company will promptly give to the Holder
written notice thereof and, if in the opinion of the Holder such registration
rights are more favorable than the registration rights provided under this
Warrant, the Holder shall so notify the Company within thirty (30) days of
receipt of the foregoing notice from the Company, whereupon such registration
rights shall automatically be deemed to be incorporated in this Warrant.

         12.4. EXPENSES OF REGISTRATION. The Company shall bear all Registration
Expenses incurred in connection with any registration, qualification and
compliance by the Company pursuant to Section 12.2 hereof. All Selling Expenses
shall be borne by the holders of the securities so registered pro rata on the
basis of the number of their shares so registered.

         12.5. REGISTRATION PROCEDURES. In the case of each registration
effected by the Company pursuant to this Section 12, the Company will keep each
Holder advised in writing as to the initiation of each registration and as to
the completion thereof. The Company will, at its expense:

                  (a) keep such registration effective for a period of one
hundred twenty (120) days or until the Holder or Holders have completed the
distribution described in the registration statement relating thereto, whichever
first occurs;

                  (b) furnish such number of prospectuses and other documents
incident thereto as a Holder from time to time may reasonably request; and

                  (c) use its best efforts to register or qualify the
Registrable Securities under the securities laws or blue-sky laws of such
jurisdictions as any Holder may request; provided, however, that the Company
shall not be obligated to register or qualify such Registrable Securities in any
particular jurisdiction in which the Company would be required to execute a
general consent to service of process in order to effect such registration,
qualification or compliance, unless the Company is already subject to service in
such jurisdiction and except as may be required by the Securities Act or
applicable rules or regulations thereunder.

         12.6.    INDEMNIFICATION.

                  (a) The Company, with respect to each registration,
qualification and compliance effected pursuant to this Section 12, will
indemnify and hold harmless each Holder, each of its officers, directors,
partners, and agents, and each party controlling such Holder, and each
underwriter, if any, and each party who controls any underwriter, against all
claims, losses, damages and liabilities (or actions in respect thereof) arising
out of or based on any untrue statement (or alleged untrue statement) of a
material fact contained in any prospectus, offering circular or other document
(including any related registration statement, notification or the like)
incident to any such registration, qualification or compliance, or based on any
omission (or alleged omission) to state therein a material fact required to be
stated therein or necessary to make the statements therein not misleading, or
any violation by the Company of the Securities Act or any rule or regulation
thereunder applicable to the Company and relating to action or inaction required
of the Company in connection with any such registration, qualification or
compliance, and will reimburse each such Holder, each of its officers,
directors, partners, and agents, and each party controlling such Holder, each
such underwriter and each party who controls any such underwriter, for any legal
and any other expenses incurred in connection with investigating or defending
any such claim, loss, damage, liability or action, provided that the Company
will not be liable in any such case to the extent that any such claim, loss,
damage, liability or expense arises out of or is

                                      -9-
<PAGE>

based on any untrue statement or omission based solely upon written information
furnished to the Company by such Holder or underwriter, as the case may be, and
stated to be specifically for use in any prospectus, offering circular or other
document (including any related registration statement, notification or the
like) incident to any such registration, qualification or compliance.

                  (b) Each Holder and Other Shareholder will, if Registrable
Securities held by it, him or her are included in the securities as to which
such registration, qualification or compliance is being effected, indemnify and
hold harmless the Company, each of its directors and officers and each
underwriter, if any, of the Company's securities covered by such a registration
statement, each party who controls the Company or such underwriter, each other
such Holder and Other Shareholder and each of their respective officers,
directors, partners, and agents, and each party controlling such Holder or Other
Shareholder, against all claims, losses, damages and liabilities (or actions in
respect thereof) arising out of or based on any untrue statement (or alleged
untrue statement) of a material fact contained in any such registration
statement, prospectus, offering circular or other document, or any omission (or
alleged omission) to state therein a material fact required to be stated therein
or necessary to make the statements therein not misleading, and will reimburse
the Company and such Holders, Other Shareholders, directors, officers, partners,
agents, parties, underwriters or control persons for any legal or any other
expenses reasonably incurred in connection with investigating or defending any
such claim, loss, damage, liability or action, in each case to the extent, but
only to the extent, that such untrue statement (or alleged untrue statement) or
omission (or alleged omission) is made in such registration statement,
prospectus, offering circular or other document solely in reliance upon and in
conformity with written information furnished to the Company by such Holder or
Other Shareholder and stated to be specifically for use in any prospectus,
offering circular or other document (including any related registration
statement, notification or the like) incident to any such registration,
qualification or compliance; provided, however, that the obligations of such
Holders and Other Shareholders hereunder shall be limited to an amount equal to
the proceeds to each such Holder or Other Shareholder of securities sold as
contemplated herein.

                  (c) Each party entitled to indemnification under this Section
12.5 (the "Indemnified Party") shall give notice to the party required to
provide indemnification (the "Indemnifying Party") promptly after such
Indemnified Party has actual knowledge of any claim as to which indemnity may be
sought, and shall permit the Indemnifying Party to assume the defense of any
such claim or any litigation resulting therefrom, provided that counsel for the
Indemnifying Party, who shall conduct the defense of such claim or any
litigation resulting therefrom, shall be approved by the Indemnified Party
(whose approval shall not unreasonably be withheld), and the Indemnified Party
may participate in such defense at such party's expense (unless the Indemnified
Party shall have been advised by counsel that actual or potential differing
interests or defenses exist or may exist between the Indemnifying Party and the
Indemnified Party, in which case such expense shall be paid by the Indemnifying
Party), and provided further that the failure of any Indemnified Party to give
notice as provided herein shall not relieve the Indemnifying Party of its
obligations under this Section 12. No Indemnifying Party, in the defense of any
such claim or litigation, shall, except with the consent of each Indemnified
Party, consent to entry of any judgment or enter into any settlement which does
not include as an unconditional term thereof the giving by the claimant or
plaintiff to such Indemnified Party of a release from all liability in respect
to such claim or litigation. Each Indemnified Party shall provide such
information as may be reasonably requested by an Indemnifying Party in order to
enable such Indemnifying Party to defend a claim as to which indemnity is
sought.

         12.7. INFORMATION BY HOLDER. Each Holder of Registrable Securities, and
each Other Shareholder holding securities included in any registration, shall
furnish to the Company such information regarding such Holder or Other
Shareholder as the Company may reasonably request in

                                      -10-
<PAGE>

writing and as shall be reasonably required in connection with any registration,
qualification or compliance referred to in this Section 12.

         12.8. RULE 144 REPORTING. With a view to making available the benefits
of certain rules and regulations of the Commission which may permit the sale of
the Registrable Securities to the public without registration, the Company
agrees to:

                  (a) Make and keep public information available, as those terms
are understood and defined in Rule 144 under the Securities Act, at all times
from and after ninety (90) days following the effective date of the first
registration under the Securities Act filed by the Company for an offering of
its securities to the general public;

                  (b) File with the Commission in a timely manner all reports
and other documents required of the Company under the Securities Act and the
Securities Exchange Act of 1934, as amended (the "Exchange Act") at any time
after it has become subject to such reporting requirements; and

                  (c) So long as the Holder owns any Registrable Securities,
furnish to the Holder forthwith upon request a written statement by the Company
as to its compliance with the reporting requirements of Rule 144 (at any time
from and after ninety (90) days following the effective date of the first
registration statement in connection with an offering of its Securities to the
general public), and of the Securities Act and the Exchange Act (at any time
after it has become subject to such reporting requirements), a copy of the most
recent annual or quarterly report of the Company, and such other reports and
documents so filed as the Holder may reasonably request in availing itself of
any rule or regulation of the Commission allowing the Holder to sell any such
securities without registration.

SECTION 13. NOTICES. Any notice or other document required or permitted to be
given or delivered to the Holder shall be delivered at, or sent by certified or
registered mail to, the Holder at Transamerica Technology Finance Division, 76
Batterson Park Road, Farmington, Connecticut 06032, Attention: Assistant Vice
President, Lease Administration, with a copy to the Lender at Riverway II, West
Office Tower, 9399 West Higgins Road, Rosemont, Illinois 60018, Attention: Legal
Department or to such other address as shall have been furnished to the Company
in writing by the Holder. Any notice or other document required or permitted to
be given or delivered to the Company shall be delivered at, or sent by certified
or registered mail to, the Company at 3510 Dunhill Street, Room 1S-304, San
Diego, California 92121, Attention: Director of Finance, or to such other
address as shall have been furnished in writing to the Holder by the Company.
Any notice so addressed and mailed by registered or certified mail shall be
deemed to be given when so mailed. Any notice so addressed and otherwise
delivered shall be deemed to be given when actually received by the addressee.

SECTION 14. NO RIGHTS AS STOCKHOLDER; LIMITATION OF LIABILITY. This Warrant
shall not entitle the Holder to any of the rights of a shareholder of the
Company except upon exercise in accordance with the terms hereof. No provision
hereof, in the absence of affirmative action by the Holder to purchase shares of
Common Stock, and no mere enumeration herein of the rights or privileges of the
Holder, shall give rise to any liability of the Holder for the Warrant Price
hereunder or as a shareholder of the Company, whether such liability is asserted
by the Company or by creditors of the Company.

SECTION 15. LAW GOVERNING. THE VALIDITY, INTERPRETATION, AND ENFORCEMENT OF THIS
WARRANT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE
STATE OF ILLINOIS WITHOUT GIVING EFFECT TO THE CONFLICT OF LAW PRINCIPLES
THEREOF.

                                      -11-
<PAGE>

SECTION 16.  MISCELLANEOUS.

                  (a) This Warrant and any provision hereof may be changed,
waived, discharged or terminated only by an instrument in writing signed by both
parties (or any respective predecessor in interest thereof). The headings in
this Warrant are for purposes of reference only and shall not affect the meaning
or construction of any of the provisions hereof

                  (b) All capitalized terms used herein and not otherwise
defined herein shall have the meanings ascribed to them in the Master Loan and
Security Agreement.

         IN WITNESS WHEREOF, the Company has caused this Warrant to be signed by
its duly authorized officer this 27th day of July, 2000.

                                        ELITRA PHARMACEUTICALS
[CORPORATE SEAL]
                                           /s/ Harry F. Hixson, Jr.
                                           ----------------------------------
                                        By: Dr. Harry F. Hixson, Jr.

                                        Title: President
                                              -------------------------------

                                      -12-
<PAGE>

                           FORM OF NOTICE OF EXERCISE

                [TO BE SIGNED ONLY UPON EXERCISE OF THE WARRANT]

                     TO BE EXECUTED BY THE REGISTERED HOLDER
                         TO EXERCISE THE WITHIN WARRANT

         The undersigned hereby exercises the right to purchase _________ shares
of Common Stock which the undersigned is entitled to purchase by the terms of
the within Warrant according to the conditions thereof, and herewith

[check one]
                                 / /   makes payment of $__________ therefor; or

                                 / /   directs the Company to issue ______
                                       shares, and to withhold ____ shares in
                                       lieu of payment of the Warrant Price, as
                                       described in Section 2.1 of the Warrant.

All shares to be issued pursuant hereto shall be issued in the name of and the
initial address of such person to be entered on the books of the Company shall
be:

         The shares are to be issued in certificates of the following
denominations:

                                        -------------------------------------

                                        [Type Name of Holder]

                                        By:
                                           ----------------------------------

                                        Title:
                                              -------------------------------

Dated:
      -----------------------------

                                      -13-
<PAGE>

                               FORM OF ASSIGNMENT
                                    (ENTIRE)

               [TO BE SIGNED ONLY UPON TRANSFER OF ENTIRE WARRANT]

                     TO BE EXECUTED BY THE REGISTERED HOLDER
                         TO TRANSFER THE WITHIN WARRANT

         FOR VALUE RECEIVED ___________________________ hereby sells, assigns
and transfers unto _______________________________ all rights of the undersigned
under and pursuant to the within Warrant, and the undersigned does hereby
irrevocably constitute and appoint _______________________________ Attorney to
transfer the said Warrant on the books of the Company, with full power of
substitution.

                                        -------------------------------------

                                        [Type Name of Holder]

                                        By:
                                           ----------------------------------

                                        Title:
                                              -------------------------------

Dated:
      -----------------------------

NOTICE

         The signature to the foregoing Assignment must correspond to the name
as written upon the face of the within Warrant in every particular, without
alteration or enlargement or any change whatsoever.

                                      -14-
<PAGE>

                               FORM OF ASSIGNMENT
                                    (PARTIAL)

              [TO BE SIGNED ONLY UPON PARTIAL TRANSFER OF WARRANT]

                     TO BE EXECUTED BY THE REGISTERED HOLDER
                         TO TRANSFER THE WITHIN WARRANT

         FOR VALUE RECEIVED _________________________ hereby sells, assigns and
transfers unto _______________________________ (i) the rights of the undersigned
to purchase ___ shares of Common Stock under and pursuant to the within Warrant,
and (ii) on a non-exclusive basis, all other rights of the undersigned under and
pursuant to the within Warrant, it being understood that the undersigned shall
retain, severally (and not jointly) with the transferee(s) named herein, all
rights assigned on such non-exclusive basis. The undersigned does hereby
irrevocably constitute and appoint __________________________ Attorney to
transfer the said Warrant on the books of the Company, with full power of
substitution.

                                        -------------------------------------

                                        [Type Name of Holder]

                                        By:
                                           ----------------------------------

                                        Title:
                                              -------------------------------

Dated:
      -----------------------------

NOTICE

         The signature to the foregoing Assignment must correspond to the name
as written upon the face of the within Warrant in every particular, without
alteration or enlargement or any change whatsoever.

                                      -15-

<PAGE>

                               AMENDMENT NO. 1 TO
                           STOCK SUBSCRIPTION WARRANT

         This Amendment No. 1 to the Stock Subscription Warrant (the
"AMENDMENT") is entered into as of August 21, 2000, by and among ELITRA
PHARMACEUTICAL, INC., a Delaware corporation (the "COMPANY"), and TBCC FUNDING
TRUST II or its registered assigns (hereinafter called the "HOLDER").

         WHEREAS, the Company and the Holder are parties to a certain Stock
Subscription Warrant dated July 27, 2000 (the "WARRANT AGREEMENT"); and

         WHEREAS, the Company and the Holder wish to amend certain portions of
the Warrant Agreement relating to the Holder's registration rights in connection
with the Holder becoming a party to the Company's Third Amended and Restated
Investor Rights Agreement (the "INVESTOR RIGHTS AGREEMENT") executed in
connection with the Company's Series E preferred stock financing.

         NOW, THEREFORE, in consideration of the mutual premises and conditions
set forth in this Amendment, the Company and the Holder mutually agree as
follows:

1.       The definition of "Warrant Price" in the Warrant Agreement shall be
         deleted in its entirety and the following shall be substituted:

                  "WARRANT PRICE - shall mean $3.25 per share, subject to
                  adjustment in accordance with Section 5 hereof."

2.       Pursuant to the terms of Section 16 of the Warrant Agreement, the
         Holder and the Company hereby agree to terminate the provisions of
         Section 12 of the Warrant Agreement relating to the Holder's
         registration rights in favor of the registration rights granted to the
         Holder under the Investor Rights Agreement.

3.       This Amendment shall be governed by and construed under the laws of the
         State of California as applied to agreements among California residents
         entered into and to be performed entirely within California.

4.       The provisions of this Amendment shall inure to the benefit of, and be
         binding upon, the successors, assigns, heirs, executors and
         administrators of the Holder and the Company.

5.       This Amendment may be executed in any number of counterparts, each of
         which shall be an original, but all of which together shall constitute
         one instrument.

                            [SIGNATURE PAGE FOLLOWS]

                                       1.

<PAGE>

         IN WITNESS WHEREOF, the undersigned have executed this Amendment as of
the date set forth in the first paragraph hereof.

                                        COMPANY:

                                        ELITRA PHARMACEUTICALS, INC.

                                        BY: /s/ DR. HARRY F. HIXSON, JR.
                                            ------------------------------------
                                            DR. HARRY F. HIXSON, JR.
                                            ------------------------------------

                                        HOLDER:

                                        TBC FUNDING TRUST II

                                        BY: /s/ [ILLEGIBLE]
                                            ------------------------------------

                                            ------------------------------------

                                       2.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00014-of-00352.parquet"}]]